Ortho Development Receives FDA Clearance on Trivicta Hip System

14 Mar 2024
www.biospace.com
Drug Approval
DRAPER, UT / ACCESSWIRE / March 14, 2024 / Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Trivicta™ Hip System. The triple-taper femoral stem facilitates an optimal fit within the canal for a diverse range of patient anatomies. The Trivicta Stem by Ortho Development "Trivicta expands our extensive primary hip portfolio and incorporates our philosophy of evolutionary innovation. The system is designed to be versatile enough to address the vast needs of patients and surgeons, accommodating both muscle-sparing and traditional surgical approaches," said Brent Bartholomew, President & CEO of Ortho Development. Designed for initial and long-term stability, Trivicta boasts a triple-tapered geometry in three separate planes and incorporates two coatings. Sintered beads provide initial stability and allow ingrowth for long-term stability, while Hydroxyapatite promotes biological fixation. Additionally, extraction and compaction broaching are integrated in one broach to preserve bone while ensuring optimal fit. Dr. Marc Hungerford, an orthopedic surgeon at Mercy Medical Center in Baltimore, MD, emphasized the benefits of the system: "The triple-taper stem geometry of Trivicta should result in a precise fit for most femoral morphologies. The unique advantage of this design is the ability to use extended offset to deliver direct lateralization independent of leg length." Trivicta will be available in the United States in the second quarter on a limited basis, with a full commercial release to follow. About Ortho Development Corporation Ortho Development Corporation designs, manufactures, and distributes orthopedic implants and related surgical instruments. The company's principal product focus is total knee and hip joint replacement. To learn more visit: . Contact: Phone: +1 801-553-9991 | Email: marketing@odev.com Contact Information: Dawn Boyd Director of Marketing and Communications dawn.boyd@orthodevelopment.com 512-508-5665 SOURCE: Ortho Development View the original press release on newswire.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.